Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05650736 · ClinicalTrials.gov registry record · Phase 2
Janus Kinase Inhibition in Granuloma Annulare
A Phase 2 study of Granuloma Annulare, sponsored by William Damsky.
- Active
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05650736: Active Phase 2 study of Granuloma Annulare, sponsored by William Damsky.
NCT05650736 is a Phase 2 study of Granuloma Annulare that is active but no longer recruiting, run by William Damsky. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05650736, a Phase 2 study of Granuloma Annulare, is active but no longer recruiting, sponsored by William Damsky.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective is to determine if JAK1 specific inhibition is effective in treating granuloma annulare (GA), a problematic inflammatory skin disease without an FDA approved treatment. The primary outcome will be the percentage change in the body surface area (BSA) involvement by GA after 6 months of treatment with abrocitinib 200 mg daily in 10 patients with moderate to severe GA affecting at least 5% body surface area (BSA).
Primary Outcome
The percentage change in the body surface area (BSA) involvement by GA after 6 months of treatment with abrocitinib 200 mg daily in 10 patients with moderate to severe GA affecting at least 5% body surface area (BSA).
Conditions Studied
Interventions
- DRUG Abrocitinib 200 mg
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-10-27 |
| Est. Completion | 2025-07-01 |
| Phase | Phase 2 |
What the registry record for NCT05650736 still lists
NCT05650736 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Granuloma Annulare appearing as the primary indexed condition, and to 1 intervention - of which Abrocitinib 200 mg is the first listed.
NCT05650736 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05650736 about?
NCT05650736 is a clinical study titled "Janus Kinase Inhibition in Granuloma Annulare". The primary objective is to determine if JAK1 specific inhibition is effective in treating granuloma annulare (GA), a problematic inflammatory skin disease without an FDA approved treatment. The primary outcome will be the percentage change in the body surface area (BSA) involvement by GA after 6 mo...
What is the current status of trial NCT05650736?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2023-10-27. Estimated completion is 2025-07-01.
What conditions does trial NCT05650736 study?
This clinical trial studies the following conditions: Granuloma Annulare.
What interventions are being tested in trial NCT05650736?
The interventions under investigation include: Abrocitinib 200 mg (DRUG).
Who is sponsoring clinical trial NCT05650736?
This trial is sponsored by William Damsky, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05650736 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05650736's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI